Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

89Bio Inc (ETNB)

89Bio Inc (ETNB)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
5.00 -0.54 (-9.75%) 04/10/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 5.00 unch (unch) 16:00 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.72
Day High
5.32
Open 5.21
Previous Close 5.54 5.54
Volume 2,195,100 2,195,100
Avg Vol 2,535,675 2,535,675
Stochastic %K 14.94% 14.94%
Weighted Alpha -54.81 -54.81
5-Day Change -1.87 (-27.26%) -1.87 (-27.26%)
52-Week Range 4.16 - 11.84 4.16 - 11.84
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 808,751
  • Shares Outstanding, K 145,984
  • Annual Sales, $ 0 K
  • Annual Income, $ -367,080 K
  • EBIT $ -385 M
  • EBITDA $ -394 M
  • 60-Month Beta 1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.44

Options Overview Details

View History
  • Implied Volatility 129.71% ( -44.48%)
  • Historical Volatility 118.22%
  • IV Percentile 94%
  • IV Rank 58.19%
  • IV High 202.78% on 01/23/25
  • IV Low 28.02% on 08/20/24
  • Put/Call Vol Ratio 1.51
  • Today's Volume 148
  • Volume Avg (30-Day) 522
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 11,545
  • Open Int (30-Day) 18,518

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 4
  • High Estimate -0.40
  • Low Estimate -0.64
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +7.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.16 +19.95%
on 04/09/25
Period Open: 7.15
9.32 -46.45%
on 03/27/25
-2.16 (-30.21%)
since 03/10/25
3-Month
4.16 +19.95%
on 04/09/25
Period Open: 6.51
11.84 -57.85%
on 02/05/25
-1.52 (-23.35%)
since 01/10/25
52-Week
4.16 +19.95%
on 04/09/25
Period Open: 10.54
11.84 -57.85%
on 02/05/25
-5.55 (-52.66%)
since 04/10/24

Most Recent Stories

More News
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Shares of Valneva VALN rose 12% on Wednesday after the company announced that it has vaccinated the first participant in a phase II study evaluating its investigational Shigella vaccine, Shigella4V2 (S4V2).This...

CTMX : 0.4946 (-1.14%)
ETNB : 4.99 (-9.93%)
VALN : 6.31 (-6.79%)
ANIP : 65.12 (-1.35%)
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune...

ALLO : 1.3700 (-3.52%)
CTMX : 0.4946 (-1.14%)
ETNB : 4.99 (-9.93%)
ANIP : 65.12 (-1.35%)
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The...

CTMX : 0.4946 (-1.14%)
ETNB : 4.99 (-9.93%)
AKBA : 1.5500 (-8.82%)
ANIP : 65.12 (-1.35%)
Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic...

CTMX : 0.4946 (-1.14%)
ETNB : 4.99 (-9.93%)
ELEV : 0.2700 (+3.85%)
ANIP : 65.12 (-1.35%)
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

Allogene Therapeutics ALLO incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had incurred...

ALLO : 1.3700 (-3.52%)
CTMX : 0.4946 (-1.14%)
ETNB : 4.99 (-9.93%)
ANIP : 65.12 (-1.35%)
89bio to Participate in the Leerink Partners Global Healthcare Conference

ETNB : 4.99 (-9.93%)
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

ETNB : 4.99 (-9.93%)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 4.99 (-9.93%)
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ETNB : 4.99 (-9.93%)
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

ETNB : 4.99 (-9.93%)

Business Summary

89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis....

See More

Key Turning Points

3rd Resistance Point 5.90
2nd Resistance Point 5.61
1st Resistance Point 5.30
Last Price 4.99
1st Support Level 4.70
2nd Support Level 4.41
3rd Support Level 4.10

See More

52-Week High 11.84
Fibonacci 61.8% 8.91
Fibonacci 50% 8.00
Fibonacci 38.2% 7.09
Last Price 4.99
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar